PRESS RELEASE published on 09/25/2025 at 20:16, 11 months 29 days ago Informations privilégiées / Communiqué sur comptes, résultats ABIONYX Pharma annonce ses résultats financiers du 1er semestre 2025. Chiffre d'affaires de 2,1 M€, pertes réduites. Trésorerie à 3,4 M€. Lauréat du plan France 2030 Chiffre D'affaires Résultats Financiers Trésorerie ABIONYX Pharma 1er Semestre 2025
PRESS RELEASE published on 09/25/2025 at 20:16, 11 months 29 days ago Inside Information / News release on accounts, results ABIONYX Pharma announces its 2025 half-year financial results, including revenue of €2.1 million and ongoing initiatives in biotech innovation. Company receives government support for sepsis research Revenue Biotech Innovation ABIONYX Pharma 2025 Financial Results Sepsis Research
PRESS RELEASE published on 09/25/2025 at 18:58, 11 months 29 days ago Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
BRIEF published on 08/28/2025 at 18:56, 1 year ago Bilan semestriel 2025 d'ABIONYX Pharma Chiffre D'affaires Trésorerie ABIONYX Pharma Soutien Financier Semestre 2025
BRIEF published on 08/28/2025 at 18:56, 1 year ago ABIONYX Pharma 2025 half-year review Treasury Financial Support Turnover ABIONYX Pharma Semester 2025
PRESS RELEASE published on 08/28/2025 at 18:51, 1 year ago Informations privilégiées / Autres communiqués ABIONYX Pharma fait le point sur son activité et sa trésorerie du 1er semestre 2025, notamment un chiffre d'affaires de 2,1 M€ provenant de sa filiale IRIS Pharma. La trésorerie s'établit à 3,4 M€ Chiffre D'affaires Biotechnologie Trésorerie ABIONYX Pharma Thérapies Innovantes
PRESS RELEASE published on 08/28/2025 at 18:51, 1 year ago Inside Information / Other news releases ABIONYX Pharma provided an update on its activity and cash position for Q2 2025. Company's revenue, cash position, and government funding details revealed Revenue Cash Position Update Government Funding ABIONYX Pharma
BRIEF published on 08/27/2025 at 19:31, 1 year ago ABIONYX Pharma en pourparlers pour un partenariat stratégique dans le sepsis Partenariat Stratégique ABIONYX Pharma Sepsis CER-001 Thérapies Innovantes
BRIEF published on 08/27/2025 at 19:31, 1 year ago ABIONYX Pharma in talks for a strategic partnership in sepsis Strategic Partnership Innovative Therapies ABIONYX Pharma Sepsis CER-001
PRESS RELEASE published on 08/27/2025 at 19:26, 1 year ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce des discussions avec un acteur majeur du sepsis pour un partenariat stratégique. L'entreprise vise à accélérer le développement de CER-001 dans le sepsis Développement Partenariat Stratégique ABIONYX Pharma Sepsis CER-001
Published on 09/25/2026 at 13:00, 31 minutes ago American Hotel Income Properties REIT LP Announces Corporate Update
Published on 09/25/2026 at 13:00, 31 minutes ago UraniumX Plans Winter Gravity Program at Murphy Lake as Q4 Assays Approach
Published on 09/25/2026 at 07:30, 6 hours 1 minute ago Tocvan Reports Positive Closed-Circuit Column Leach Results at Gran Pilar
Published on 09/25/2026 at 12:26, 1 hour 5 minutes ago VitrA Tiles Introduces "The Code" concept and the New Codes of Design at Cersaie Fair
Published on 09/25/2026 at 10:00, 3 hours 31 minutes ago AI and supply chains open new pathways to systemic stress as risks become more interconnected, find Swiss Re Institute and LSE
Published on 09/25/2026 at 09:09, 4 hours 22 minutes ago flatexDEGIRO sets course for next phase of growth
Published on 09/25/2026 at 07:00, 6 hours 31 minutes ago ENGIE mobilise une aide exceptionnelle de 54 millions d'euros pour soutenir les ménages les plus fragiles face à la hausse des prix de l'énergie
Published on 09/24/2026 at 18:31, 19 hours ago LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:00, 19 hours 31 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 19 hours 31 minutes ago GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
